Ph.D., CEO & CO-FOUNDER, Guardant Health
Helmy Eltoukhy, PhD, is currently the co-founder and CEO of Guardant Health, the market leader in liquid biopsies. Helmy’s prior startup, Avantome, was a leader in low-cost sequencing before being acquired by Illumina. Helmy served as the senior director of scientific research at Illumina, where he was responsible for the development of novel chemistries, hardware, and informatics for genetics analysis systems.Helmy began his career at the Stanford Genome Technology Center, where he invented the first semiconductor sequencing platform and the first base-calling algorithm for next-gen sequencing. He earned his PhD, MS, and BS degrees in electrical engineering from Stanford.
Cancer’s Tweet: 160bp Snapshots into Cancer’s Hidden Evolution
Improvements in liquid biopsies have enabled surprise findings in the evolution of cancer, including radical increases in gene amplifications, tumor heterogeneity not previously captured by tissue NGS, and undiscovered potential biomarkers. These findings point to diverse new uses and increased utility for liquid biopsies, and the promise of better patient outcomes.